Epeleuton flops for liver protection
Epeleuton, a second‐generation synthetic n‐3 fatty acid derivative of eicosapentaenoic acid, falls short of improving alanine aminotransferase or liver stiffness in patients with nonalcoholic fatty liver disease (NAFLD), according to a study. However, it has potential for cardiovascular risk reduction by simultaneously targeting hypertriglyceridemia, hyperglycaemia, and systemic inflammation.
